Bupropion

Generic Name
Bupropion
Brand Names
Aplenzin, Auvelity, Budeprion, Contrave, Forfivo, Wellbutrin, Zyban
Drug Type
Small Molecule
Chemical Formula
C13H18ClNO
CAS Number
34911-55-2
Unique Ingredient Identifier
01ZG3TPX31
Background

Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the upta...

Indication

Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation.
...

Associated Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder (MDD), Obesity, Seasonal Affective Disorder (SAD)
Associated Therapies
Smoking, Cessation, Weight Loss
Clinical Trials
Related News

Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea

First Posted Date
2020-06-24
Last Posted Date
2024-12-09
Lead Sponsor
Pfizer
Target Recruit Count
370212
Registration Number
NCT04446039
Locations
🇰🇷

Pfizer, Seoul, Korea, Republic of

Combination of Novel Therapies for CKD Comorbid Depression

First Posted Date
2020-06-09
Last Posted Date
2023-08-31
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
201
Registration Number
NCT04422652
Locations
🇺🇸

University of Washington, Seattle, Washington, United States

🇺🇸

Parkland Health and Hospital System, Dallas, Texas, United States

🇺🇸

UT Southwestern and Affiliates, Dallas, Texas, United States

and more 1 locations

Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes

First Posted Date
2020-05-14
Last Posted Date
2022-04-13
Lead Sponsor
Rose Research Center, LLC
Target Recruit Count
26
Registration Number
NCT04388319
Locations
🇺🇸

Rose Research Center, Raleigh, North Carolina, United States

Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion

Phase 4
Withdrawn
Conditions
Major Depressive Disorder
Interventions
Drug: Duloxetine
Drug: Bupropion
First Posted Date
2020-05-14
Last Posted Date
2020-10-19
Lead Sponsor
Alto Neuroscience
Registration Number
NCT04388189

Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)

First Posted Date
2019-10-23
Last Posted Date
2023-07-27
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
12
Registration Number
NCT04135937
Locations
🇺🇸

Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States

Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression

Phase 4
Terminated
Conditions
Depression
Interventions
Drug: Escitalopram
Drug: Bupropion
First Posted Date
2019-06-20
Last Posted Date
2023-04-18
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
18
Registration Number
NCT03993457
Locations
🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

CPT-SMART for Treatment of PTSD and Cigarette Smoking

First Posted Date
2019-06-07
Last Posted Date
2024-10-04
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
120
Registration Number
NCT03978442
Locations
🇺🇸

Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States

PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness

First Posted Date
2019-05-15
Last Posted Date
2024-12-05
Lead Sponsor
University of California, San Francisco
Target Recruit Count
120
Registration Number
NCT03950427
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment

Phase 4
Completed
Conditions
Major Depression
Interventions
Drug: escitalopram
Drug: bupropion
First Posted Date
2019-04-25
Last Posted Date
2019-04-25
Lead Sponsor
University of Tartu
Target Recruit Count
135
Registration Number
NCT03927950
Locations
🇪🇪

Department of Psychiatry, University of Tartu, Tartu, Estonia

Bupropion and Cigarette-Related Cues in Smokers

Phase 1
Completed
Conditions
Smoking
Smoking, Tobacco
Interventions
Other: Placebo
Drug: Bupropion
First Posted Date
2019-04-18
Last Posted Date
2019-04-18
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
34
Registration Number
NCT03920319
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy